The Maker of Ozempic Is Trying to Block Compounded Versions of Its Blockbuster Drug
Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do safely. It’s the latest escalation in a brewing war between pharmaceutical companies and compounders.
Read more at Wired
Topics
-
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Politics - The Hill - October 23 -
Ozempic maker Novo Nordisk nudges higher profit forecast
Business - MarketWatch - November 6 -
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
Business - CNBC - October 23 -
Ozempic, Wegovy popularity leads to rise of fake weight loss drugs
Top stories - CBS News - November 9 -
Chancellor and BoE governor call for UK to rebuild ties with EU
Business - Financial Times - 6 days ago -
Britain’s bold plan to create super funds
Business - Financial Times - 6 days ago -
Employers Get Pressure to Pay for Drugs Like Wegovy
Business - The Wall Street Journal - 2 days ago -
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Business - MarketWatch - Yesterday
More from Wired
-
News Influencers Have Eclipsed Traditional Media
Tech - Wired - 17 minutes ago -
China’s Surveillance State Is Selling Citizen Data as a Side Hustle
Tech - Wired - 47 minutes ago -
Relevant! Relevant! Relevant! At 50, Microsoft Is an AI Giant, Open-Source Lover, and as Bad as Ever
Tech - Wired - 1 hour ago -
The AI Reporter That Took My Old Job Just Got Fired
Tech - Wired - 2 hours ago -
Google Selling Chrome Won’t Be Enough to End Its Search Monopoly
Tech - Wired - 7 hours ago